BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Hematol. Nov 20, 2026; 12(3): 126171
Published online Nov 20, 2026. doi: 10.5315/wjh.126171
Table 1 Randomized controlled trials and pooled analysis of viscoelastic testing-guided transfusion in cirrhosis
Ref.
Design and sample size
Clinical setting
Assay
Transfusion outcome
Bleeding and mortality outcome
Rout et al[13]RCT, 30 vs 30, IndiaAcute variceal bleedingTEG4 patients (13.3%) vs all patients (100%) transfused, P < 0.001Rebleeding at 5 days 3.3% vs 13.3%, P = 0.167; rebleeding at 42 days 10.0% vs 36.7%, P = 0.012; 6-week mortality 13.3% vs 26.7%, P = 0.176
Kumar M et al[14]RCT, 49 vs 47, IndiaNonvariceal upper GI bleeding in advanced cirrhosisTEGAll three components (plasma, platelets, and cryoprecipitate) given to 26.5% vs 87.2%, P < 0.001Failure to control bleeding, rebleeding, and mortality similar in both arms
Vuyyuru et al[15]RCT, 29 vs 29, IndiaHigh-risk invasive liver-related proceduresTEG9 patients (31%) vs all patients (100%) transfusedNo procedure-related bleeding through 5 days in either arm
Biswas et al[16]RCT, three arms of 29, IndiaSevere thrombo­cytopenia before invasive proceduresTEGPlatelets: 4/29 (13.8%) with TEG, 29/29 (100%) with standard care, and 4/29 (13.8%) on demand; P < 0.001 for TEG vs standard careMinor bleeding in 3 (10%) with TEG vs 1 (3.4%) in each comparator arm, P = 0.43; no bleeding-related death
Kumar R et al[17]RCT, 20 vs 20, SingaporeElective procedures, predominantly low to intermediate riskROTEM40% vs 100% transfused, P < 0.001; less plasma, P < 0.001, and fewer platelets, P = 0.046No clinically significant bleeding; 30-day and 90-day mortality did not differ significantly
Hartmann et al[4]Meta-analysis of 5 earlier RCTs (302 patients)Cirrhosis, including liver transplantationTEGPlatelet use RR 0.17, 95%CI 0.03-0.90, P = 0.047-day mortality RR 0.52, 95%CI 0.30-0.91, P = 0.02


Write to the Help Desk